Group 1 - The core focus of the article is Novo Nordisk's advancement of the weight loss drug Amycretin, which targets GLP-1 for diabetes and weight management through both subcutaneous injection and oral administration [1] Group 2 - Amycretin is entering the third phase of clinical development, indicating significant progress in its research and potential market introduction [1]